Symlin “Approvable” Letter Will Be Addressed By Ongoing Trials, Amylin Says
Executive Summary
Amylin hopes that data from two ongoing open-label Symlin trials will address questions outlined by FDA in an "approvable" letter for the diabetes agent
You may also be interested in...
FDA Investor Relations: SEC Agreement Close, “Complete Response” Reg Not
FDA's role in policing investor communications about regulatory actions will continue to receive attention in 2004 after the Securities & Exchange Commission opened investigations into Biopure and Amylin
FDA Investor Relations: SEC Agreement Close, “Complete Response” Reg Not
FDA's role in policing investor communications about regulatory actions will continue to receive attention in 2004 after the Securities & Exchange Commission opened investigations into Biopure and Amylin
Amylin Exenatide NDA Filing Expected Mid-2004; Symlin Launch in Q1
Amylin is eyeing a mid-2004 filing date for its exenatide NDA